| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 429.53 | 0.9% | 7.1% |
| Total Income | 439.09 | 1.6% | 7.0% |
| Expenditure | 390.60 | 0.1% | 7.1% |
| PBT | 48.49 | 12.0% | 5.9% |
| Net Profit | 35.57 | 10.3% | 8.2% |
| OPM | 14.91% | 0.20pp | 0.40pp |
| NPM | 8.10% | 0.78pp | 0.09pp |
| EPS | 5.28 | 10.4% | 8.2% |
Steady YoY growth masks QoQ pressure; margin recovery path credible but distant
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit Q2 revenue and PAT guidance; H1 grew 15.4% YoY. Cut FY28 EBITDA margin target (20% → 18–19%).
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Vishnu Chemicals delivered steady 7.1% YoY revenue growth and maintained 14.9% OPM, but Q2 PAT fell 10.3% QoQ amid logistics headwinds and export volatility. Management cut FY28 EBITDA margin target to 18–19% from prior 20%, citing near-term challenges. The multi-year growth story (DMSO, chromium JV, backward integration) is credible but execution-dependent and weighted 18+ months ahead. Capex intensity (₹300 Cr next 12 months) pressures near-term cash; risk is that near-term margin compression persists beyond management's Q4 recovery thesis.
₹429.5 Cr
Revenue · +7.1% YoY₹35.6 Cr
Reported PAT · +8.2% YoYFlat
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 revenue ~₹429.5 Cr, up 7% YoY to ₹429.53 Cr from ₹401.15 Cr
METDelivered ₹429.5 Cr, 7.1% YoY growth confirmed
EBITDA ₹64 Cr, up 10% YoY; margin 14.9% vs 14.5% prior
METOPM 14.9% confirmed; EBITDA margin expanded 40 bps YoY
PAT ₹35.57 Cr, up 8.2% YoY from ₹32.88 Cr; margin 8.3%
METPAT ₹35.6 Cr, 8.2% YoY, NPM 8.1% — matches
Targeting 18%–19% EBITDA margin by FY28
OVERSTATEDPrior call stated 'targeting 20% by FY28' — this is a 100–200 bps cut
Export sales down due to supply chain disruption, freight impact 20%–25% of selling price
METQ2 exports down YoY; leather business hardest hit; value loss INR20–30 Cr/quarter acknowledged
Earnings quality
What changed since the last call
FY28 EBITDA margin guidance
DowngradePrior call: 20% target by FY28. This call: 18–19% for next year (FY28). Cut of 100–200 bps; cited macro headwinds, logistics, execution risk on new ventures
Capex guidance
UpgradePrior FY27: ₹200–250 Cr. This call: ₹300 Cr next 12 months (implies ~₹490 Cr H1+next 12m vs ₹200–250 Cr FY27). Higher investment in DMSO, chromium, oxide greenfield
Export outlook
DowngradeQ1 FY27 assumed export stability; Q2 call: leather exports down significantly (₹20–30 Cr/quarter loss), recovery delayed to Q4 (uncertain)
Strontium carbonate opportunity
NewQ1 contributed ~₹25 Cr revenue; Q2 stabilized but profitability below expectations; now targeting approval wins from Indian customers (import replacement story) — early stage
The Q&A
Analysts pressed hard on margins (Sagar Jethwani, Mahek Talati, Dev Mehta). Management hedged: 18–19% for FY28 not Q4, acknowledged logistics as 3% quarterly drag, deferred DMSO/chrome profitability color ('very early,' 'volume-driven'). On capex, management candid: ₹300 Cr next 12m, peak debt ₹800 Cr. Held firm on macro recovery thesis (Q4/Q1 improvement) but offered no quarterly targets. Tone cautious but not defensive.
Export sales loss — Sagar Jethwani, PhillipCapital
AnsweredLoss primarily in leather (freight 20–25% of price). Value loss INR20–30 Cr/quarter. Recovery by Q4 as pricing normalizes.
Margin guidance — Sagar Jethwani, PhillipCapital
PartialMargins volatile; backward integration should improve both. Directional improvement expected in margins and product mix. Oxide business gaining. Will target 15%–19% EBITDA for next year.
Strontium carbonate — Nirali Gopani, Unique PMS
AnsweredNumbers similar to last quarter but profitability not as expected. Now getting major customer approvals in India (import replacement). Optimistic for future but early stage.
Capex and guidance — Sheet Shah, Sameeksha Capital
AnsweredTotal capex ₹152 Cr so far; next 12 months ₹300 Cr. Already reflected in balance sheet (increase in debt and accruals).
Chromium JV — Kaushal Sharma, Equinox Capital
PartialNo confidential color on investment; plant greenfield in Visakhapatnam. Targeting 20% EBITDA margin (volume-driven, higher value-add product). Chromium import ~1,700–1,800 tons/year in India, growing 12–13% YoY. 60–70% will be exported.
DMSO margin trajectory — Dev Mehta, Unique PMS
PartialNo guidance yet; targeting 50–60% operating level first year, ideally 70% second year. Will give visibility once plant runs and customer approvals done. At gross margin 35–40%, EBITDA could be 'very promising' given volumes.
South Africa plant — Anukool Arora, Shagun Capital
AnsweredTargeting Q4 start for shipment from South Africa to India. Mining operations running well; focus on operational safety and output consistency.
Margin recovery timeline — Darshil Jhaveri, Crown Capital
DodgedVery early to comment; Q3 seen as positive trend vs Q2. Volume improving, logistics subsiding, backward integration benefits kicking in. 18–19% EBITDA margin target for next financial year.
FY28 margin guidance — Mahek Talati, Agility Advisors
PartialConsolidated for first half FY27 delivered 15% EBITDA margin. 3% logistics drag quarterly in Q2. Expect subsiding in quarters to follow. Also product launch (DMSO) and backward integration (combination) will improve margins. Targeting 15–18% H2.
Debt trajectory — Dev Mehta, Unique PMS
AnsweredCurrent debt ₹717 Cr including working capital; will be ₹800–₹820 Cr (peak). Capex-driven; internal accruals funding rest. ~₹190 Cr spent H1, ₹330 Cr more to come over next 12 months.
Guidance
H2 growth positive trend vs Q2; margin recovery Q4/Q1
MediumAssumes logistics stabilize and export volume recovery by Q4. H1 delivered 15.4% growth; implies FY27 growth 10–12% range
FY28 EBITDA margin target 18–19%
MediumDown from prior 20% guidance. Assumes DMSO ramp, chromium JV contribution, backward integration benefit, product mix improvement. Logistics normalization critical.
H2 FY27 EBITDA margin 15–18%
LowHedged guidance; wide range reflects execution risk on new ventures and macro uncertainty
Next 12 months ₹300 Cr capex
HighIncludes DMSO (₹250+ Cr), chromium expansion (₹50 Cr via DCX JV), oxide/specialty chemicals. H1 spent ₹190 Cr; revised from prior ₹200–₹250 Cr FY27
Risks the call surfaced
Logistics / geopolitical
HighFreight costs up 20–25% of leather export selling price due to West Asian geopolitical tensions. Leather volume loss ₹20–30 Cr/quarter. Recovery timeline Q4 uncertain.
Capex execution
MediumDMSO plant (₹250+ Cr) targeting Q1 FY28 ramp; greenfield project in Odisha. Chromium JV targeting Q4 FY27 production startup. Both critical for FY28 18–19% margin target.
Margin volatility
HighSulfuric acid, energy (power/gas), raw materials volatile. Management notes macro headwinds impacting EBITDA margins. New ventures (DMSO, chromium) are volume-driven; utilization risk at lower capacity implies margin compression.
Market concentration
MediumExport sales skewed toward leather (Americas/Europe); geopolitical risk high. Domestic market (58%) increasingly important but concentrated in auto/infra. Strontium carbonate early-stage; profitability below expectations.
Working capital
LowInventory days rose from 62 to 72–73 days; receivables days 62–73 days (similar to prior year). Macro environment and logistics cost caution driving buildup. If export recovery delayed, WC pressure persists.
Management
Score 6/10. Transparent on headwinds (logistics, export losses) and capex costs. Hedged on new venture profitability ('very early,' 'too early to comment'). Avoided specific DMSO/chromium margins until ramp clarity. NDA-shielded chromium investment specifics. Candid on debt trajectory and cash drain. Q2 numbers matched guidance exactly (₹429.5 Cr revenue, 8.2% PAT growth, 14.9% margin). Cut FY28 EBITDA target from 20% to 18–19% (execution risk noted). Capex tracking; ₹190 Cr H1 vs ₹152 Cr guided (on-track for ₹300 Cr 12m). Backward integration (barium) capex completed; payback showing.
1 · Q4 FY27 (Jan 2027)
Chromium metal capacity commissioning at Visakhapatnam via DCX JV; first shipments to Airbus supply chain
2 · Q1 FY28 (Apr 2027)
DMSO plant ramp; company targeting 50–60% operating level first year, 70% by second year
3 · Q4 FY27 onwards
South Africa plant shipments begin; mining operations stable; commodity tailwind if chrome ore prices firm
Capex intensity (₹300 Cr next 12 months) pressures near-term cash; risk is that near-term margin compression persists beyond management's Q4 recovery thesis.
The ₹35.6 Crore Quarter: Steady YoY, But Margin Target Just Got 200 Basis Points Cheaper
Q2 PAT fell 10.3% quarter-on-quarter despite 8.2% year-on-year growth. Management's response: ratchet down FY28 EBITDA margin guidance from 20% to 18–19%, signal capex stress ahead, and admit export logistics remain broken. The market has already priced it in.
₹35.6 Cr
+8.2% YoY
₹35.6 Cr
-10.3% QoQ (implied)
14.9%
+40 bps YoY
18–19%
Cut 100–200 bps from prior 20%
Vishnu Chemicals posted a textbook steady-quarter on the headline: revenue up 7.1% year-over-year to ₹429.5 Cr, net profit up 8.2% to ₹35.6 Cr. But the quarter-on-quarter story tells a different tale. PAT fell 10.3% sequentially — signaling deceleration into Q2 despite strong H1 growth of 15.4%. The culprit is not operational: it is logistics. Management quantified export business pressure at ₹20–30 crore lost per quarter in leather sales, driven by geopolitical freight cost inflation (20–25% of leather export selling price). And on guidance, the company took an axe to forward expectations: FY28 EBITDA margin target ratcheted down from 20% (stated last quarter) to 18–19% effective this call. That is a 100–200 basis-point cut in one quarter — a material reset that signals management's conviction on near-term execution has weakened.
The tension: strong organic but margin headwinds are real
H1 FY27 grew revenue 15.4% year-over-year (₹862.3 Cr from ₹748.1 Cr in H1 FY26), implying Q1 was very strong and Q2 decelerated. EBITDA margin held at 14.9% — up 40 basis points year-over-year despite logistics drag — which shows underlying operational resilience. But the PAT margin compressed to 8.1% from implied 8.7% in H1, meaning Q2 felt the full brunt of freight cost inflation. Management's own math: logistics costs consumed 20.9% of export sales in Q2 versus 10.7% consolidated in Q1, a near doubling that eroded about 300 basis points of quarterly margin.
Q2 revenue ~₹429.5 Cr, up 7% YoY
Delivered ₹429.5 Cr, 7.1% YoY. Confirmed.
Supported
EBITDA margin 14.9%, up 40 bps YoY
OPM 14.9% confirmed; margin expansion 40 bps YoY
Supported
PAT ₹35.57 Cr, up 8.2% YoY
PAT ₹35.6 Cr, 8.2% YoY, NPM 8.1%
Supported
FY28 EBITDA margin target 20% (from prior call)
This call: 18–19% for FY28. Cut of 100–200 bps.
Overstated (guidance reset downward)
Export sales down due to freight, ~₹20–30 Cr/quarter loss
Leather exports down YoY; freight impact 20–25% of price. Value loss acknowledged.
Supported
What changed on this call
Margin guidance downgrade (FY28 target 20% → 18–19%). The biggest signal. Prior call stated 20% EBITDA margin target by FY28; this call cuts it to 18–19% for the same fiscal year. That is a 100–200 basis-point reset in one quarter, citing macro headwinds, logistics drag, and execution risk on new ventures (DMSO, chromium JV) as the rationale. Credibility grade: B (hit Q2 numbers but reset forward guides lower).
Capex guidance raised (FY27 ₹200–250 Cr → next 12 months ₹300 Cr). Prior guidance was ₹200–250 Cr for full FY27; this call sets next 12 months at ₹300 Cr (implies ~₹490 Cr annualized vs. ₹250 Cr prior FY27 ceiling). H1 spent ₹190 Cr; remaining ~₹330 Cr over next 12 months. The step-up is driven by DMSO plant (greenfield, Odisha, ~₹250+ Cr), chromium metal JV (₹50 Cr via DCX partnership), and oxide/specialty chemical capacity. Peak debt expected ₹800–₹820 Cr mid-FY27.
Export outlook downgrade. Q1 FY27 assumed export stability; Q2 call now quantifies leather exports down significantly (₹20–30 Cr/quarter loss), recovery delayed to Q4 (timeline uncertain). This is a material re-forecast versus the prior quarter's baseline.
Domestic sales mix strategy gaining ground. Domestic sales now 58% of consolidated Q2 (vs. 45% in Q1), a deliberate shift to hedge export volatility. This supports organic growth resilience but signals management's caution on near-term export outlook.
Margin math and the catalyst timeline
Management is betting on three levers to recover from 14.9% (Q2) to 18–19% (FY28): (1) DMSO plant ramp (Q1 FY28 start): 10,000 tons/year capacity; targeting 50–60% operating level first year, 70% by year two. Gross margin 35–40%, EBITDA margin framed as 'very promising' but no specific guidance given until plant runs and customer approvals close. (2) Chromium metal JV (Q4 FY27 startup): 6,000 tons/year high-purity capacity via DCX partnership at Visakhapatnam. Targeting 20% EBITDA margin (volume-driven); 60–70% export-focused to aerospace/defense. (3) Backward integration payback: Barium capex complete (₹375 Cr); capacity utilization at 70%; margin recovery underway. Domestic specialty chemicals (oxide, acid) gaining share.
The timeline matters: Q4 FY27 (est. Jan 2027) is chromium metal startup; Q1 FY28 (Apr 2027) is DMSO ramp. That means FY28 margin target assumes both come online AND run at sufficient utilization within a 12-month window. Execution risk is real.
H1 FY27 revenue growth 15.4% YoY outpaces standalone 7.1% Q2, showing strong start to year
EBITDA margin resilience: 14.9% Q2 vs 14.5% YoY despite freight drag shows operational strength
Backward integration (barium) capex complete; payback underway; diversification into specialty chemicals working
Domestic sales mix (58%) growing faster than export; insulates from geopolitical freight volatility
Q2 PAT fell 10.3% QoQ despite YoY growth; near-term momentum faltering
FY28 margin guidance cut 100–200 bps in one quarter; signals execution/macro risk not fully baked into prior plan
Capex intensity rising (₹300 Cr next 12m); peak debt ₹800–₹820 Cr; ROI and cash generation at risk near-term
New venture margins deferred ('very early,' 'volume-driven'); DMSO and chromium profitability unproven at scale
Export leather recovery timeline (Q4) uncertain; if geopolitical tensions persist, ₹20–30 Cr/quarter loss continues
Working capital pressure: inventory +10 days to 72–73; if export recovery delayed, working capital tension persists
Logistics and geopolitical freight volatility persist
HIGHLeather exports (42% of revenue mix) down ₹20–30 Cr/quarter due to freight at 20–25% of export price. Q4 recovery timeline uncertain. If West Asian tensions continue, margin pressure persists into FY28, undermining 18–19% target.
Capex execution slippage on new ventures (DMSO, chromium JV)
MEDIUMDMSO plant (greenfield, Odisha) targeting Q1 FY28 ramp; chromium JV Q4 FY27 startup. Both are critical for margin recovery. Delays or cost overruns erode ROI and push debt peak beyond ₹800–₹820 Cr guidance.
New venture profitability underperforms (utilization, pricing)
MEDIUMDMSO margins (35–40% gross, EBITDA 'very promising') and chromium (20% EBITDA 'volume-driven') are assumptions not yet validated. If either ramps below 50% utilization or faces pricing pressure, FY28 18–19% target misses.
Macro/commodity price volatility (sulfuric acid, energy, raw materials)
HIGHSpecialty chemicals (chrome, barium, strontium) are commodity-input-dependent. No hedging disclosed; margin recovery assumes commodity prices stabilize. Energy cost inflation pressures operating leverage.
Working capital pressure from delayed export recovery
MEDIUMInventory days up 10 days to 72–73 due to macro caution and elevated logistics costs. If export volume recovery delays beyond Q4, receivables days stretch, tightening cash and delaying debt paydown.
Market concentration in domestic auto/infra and export leather
MEDIUMDomestic 58% tilted toward auto and infra (cyclical sectors); export 42% skewed toward leather (geopolitical sensitive). Strontium carbonate profitability below expectations despite ₹25 Cr Q1 revenue. Diversification incomplete.
How the street is positioned (and why the stock fell 24.66% from ATH)
The stock closed at ₹560.5 on day 1 of this report, down 24.66% from its all-time high of ₹744. It sits below all three moving averages (SMA20 ₹576.52, SMA50 ₹644.52, SMA200 ₹587.58), and RSI 40.4 signals neutral/oversold territory. Volume is normal; price trend is neutral. This drawdown is not a panic sell — it is a measured re-rating.
The market's logic is clear: the 20% → 18–19% margin guidance cut, combined with capex ramp to ₹300 Cr next 12 months and near-term logistics drag, erases near-term earnings lift. The stock has already repriced the downside. Institutional ownership is stable: FII at 2.51% (up 21 bps from Q1 FY27's 2.30%) and DII at 5.94% (up 22 bps from 5.72%). Promoter steady at 69.21%. Neither FII nor DII is bailing; both are incrementally adding. This suggests sophisticated investors see value at current levels, betting the capex and new ventures deliver the medium-term recovery.
Valuation context: the 24.66% drawdown from ATH leaves room for upside if FY28 margins beat 18–19% (unlikely near-term, but possible by late FY28) or if capex generates ROI faster than feared. But the stock is not yet cheap enough to offset execution risk — it is fairly valued for a 'show me' story.
The debate
The honest read: Vishnu delivered a steady quarter operationally but signaled execution caution via guidance reset and capex step-up. The company is navigating near-term logistics headwinds (Q2–Q4) while betting capex and new ventures drive a multi-year margin uplift (FY28 onwards). The near-term risk (logistics persist, capex overrun, utilization misses) outweighs the medium-term upside (DMSO, chromium, backward integration). The market has already priced in the downside (stock -24.66% from ATH), and institutional ownership is stable. At ₹560, the stock is a Hold — not a buy until capex ROI materializes or export volumes recover, but not a sell either because the underlying story is credible. The next quarter will clarify: if Q3 margins trend upward or leather volumes stabilize, the upside re-rates; if Q3 margins compress further, the stock tests ₹480–₹500.
1 · Q3 EBITDA margin trend and export volume stabilization
Management guided Q3 as 'positive trend vs Q2' but offered wide ranges (15–18% H2 EBITDA margin). The key: does Q3 margin improve QoQ? Leather export recovery is critical; if ₹20–30 Cr/quarter loss persists, margin compression accelerates. Watch for management commentary on Q4 recovery timeline (certain or uncertain).
2 · DMSO plant customer approvals and ramp visibility
DMSO plant is expected Q1 FY28 startup (Apr 2027, ~6 months away). By Q3 FY27 earnings (late Jan 2027), management should provide update on customer approvals, pricing, and first-year utilization target. No visibility = execution risk.
3 · Capex tracking and debt trajectory
H1 capex ₹190 Cr; next 12 months ₹300 Cr. Q3 disclosure will show YTD capex and revised FY27 outlook. If capex accelerates or overshoots, peak debt could breach ₹820 Cr guidance, pressuring credit metrics and free cash flow. Watch for debt/EBITDA trend and management commentary on refinancing risk.
Vishnu Chemicals is a steady-operator hit by near-term headwinds (logistics, export volatility, capex intensity) that management believes it can overcome via new ventures and backward integration payback. The 7.1% Q2 revenue growth and 14.9% EBITDA margin are resilient on the operational level; the risk is that margins stay pinned at 14–15% through FY28 if execution slips or macro headwinds persist. The stock has repriced from ₹744 to ₹560 — a fair re-rating for the guidance reset, but not yet cheap enough to offset the execution bet ahead. Hold and watch for Q3 margin inflection and capex ROI color by late January.